Close Menu

Mireven

Australian microRNA drug firm MiReven announced this week the publication of in vitro data validating the role of miR-7-5p in cancer.

Though not as advanced a therapeutic technology as its RNAi cousin, microRNA received a lot of positive attention from the investment community in 2012, with the top companies in the space pulling in nearly $150 million in financing dollars over the past year.

As it awaits the publication of in vitro data from its lead cancer program, Australian microRNA drugs startup MirEven has moved into proof-of-concept animal studies to test various oligo chemistries and delivery technologies, a company executive said this week.

Australian microRNA drug developer Mireven said last week that it has received an additional A$500,000 ($511,000) from early-stage investment group Medical Research Commercialization Fund, bringing the total investment MRCF has made in the company to A$1.1 million.

Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.